Skip to search formSkip to main contentSkip to account menu

BC-3781

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DiterpenesThioglycolates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Formulations pharmaceutiques injectables de lefamuline
La presente invention concerne une formulation pharmaceutique injectable comprenant un compose de la formule (I), ladite… 
2015
2015
Efficacy of Novel Extended Spectrum Pleuromutilins Against E. coli In Vitro and In Vivo
Among the resistant bacterial pathogens causing serious infections E. coli is one of most worrisome since multi-drug resistant… 
2013
2013
A Phase II clinical study of BC-3781 , a pleuromutilin antibiotic , in the 1 treatment of patients with acute bacterial skin and skin structure 2 infection
2012
2012
Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics
ABSTRACT MIC and disk diffusion quality control (QC) ranges were established for two new pleuromutilin antimicrobials (BC-3205… 
2010
2010
Activity of BC-3781, a Novel Pleuromutilin Compound, Tested against Clinical Isolates of MRSA, Including Molecularly Characterized Community-Acquired and Hospital-Associated Strains
Background: BC-3781 has a unique mode of action which interferes with bacterial protein synthesis without cross-resistance (R) to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)